Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia

NCT01598168 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Stopped slow recruitment

Conditions

Heparin-induced Thrombocytopenia

Interventions

DRUG: Rivaroxaban

Sponsor

McMaster University